Biotech & Pharma

Novo Nordisk has licensed its Parkinson's cell therapy program to Cellular Intelligence and closed its internal discovery unit—a structural shift mirrored by pharma companies worldwide. NVIDIA's BioNeMo platform has made AI drug discovery operational infrastructure, not experimental technology. NVO shares rose 25% in a month as markets price in AI-native pipelines as durable competitive advantages.

Six or more FDA PDUFA decisions are expected in 2026 covering antibody-drug conjugates, checkpoint inhibitors, and precision molecules — the densest oncology approval calendar in years. AbbVie's EHA 2026 data showed venetoclax plus obinutuzumab delivered a median eight years to next treatment in untreated CLL. A Century Therapeutics iPSC cell therapy for type 1 diabetes, affecting nine million people globally, extends the catalyst window into Q1 2027.

A wave of antibody-drug conjugate combination trials across the US and China is converging on a narrow 2026–2027 regulatory window. China's NMPA has already approved a fruquintinib-sintilimab combination for renal cell carcinoma, validating the global strategy. Portfolio managers holding multiple names in this cluster face correlated binary-event risk in the second half of 2026.